25 ppm Complete Feed Production in Broiler Integrations

In vertically integrated broiler operations, semduramicin sodium is incorporated into complete feed at a final concentration of 25 ppm, equivalent to 22.7 g per short ton or 25 g per metric ton of finished mash, pellet, or crumble. The intermediate addition rate for a 5% premix is 0.5 kg per metric ton; the arithmetic expansion from Type A medicated article to Type C complete feed is therefore 1:2,000 by mass. Under United States conditions of use, 21 CFR 558.555 recognises semduramicin sodium for prevention of coccidiosis in broiler chickens caused by Eimeria tenella, E. acervulina, E. maxima, E. necatrix, and E. brunetti. In the European feed additive framework, the substance is authorised under Regulation (EC) No 1831/2003 for chickens for fattening; current Annex entries and national approvals determine withdrawal intervals, with 5 days frequently cited where a pre-slaughter withdrawal is required. Feed mills producing such medicated complete feed operate under 21 CFR Part 225/226 or Regulation (EU) No 183/2005 hygiene requirements, depending on jurisdiction, and the site must maintain daily medicated feed inventory reconciliations in 1 kg or finer resolution.

Batch sequencing in the mill generally places the semduramicin sodium premix in the micro-ingredient batching hopper after grain, soya meal, and mineral sources but before liquid fat addition. Horizontal double-ribbon or paddle mixers are operated to a coefficient of variation below 5% before the first finished feed batch is released; if the mixer has a validated mixing time curve, the semduramicin premix is added at the point where tracer studies show the fastest homogeneous distribution without over-mixing. Steam conditioning at 70–85°C followed by ring-die pelleting and crumble roll sizing does not generally require a semduramicin-specific temperature exemption; however, the mill should confirm recovery in pelleted feed through in-house HPLC release testing, with acceptance typically between 90% and 110% of label concentration. Finished product types include complete broiler starter, grower, and finisher feeds in mash, pelleted, and crumble formats. The use of semduramicin sodium in laying hens, turkeys, horses, or other equines is not authorised; the mill must apply flush sequencing before producing non-broiler feed after semduramicin sodium batches.

When a Feed Mill Switches From Monensin to Semduramicin Sodium

When a feed mill changes ionophore programmes, uncontrolled residual monensin can act as an additional ionophore load in the first semduramicin sodium batches. The operational issue is not merely advisory because carryover from a previous medicated feed can shift the total ionophore exposure above the intended 25 ppm semduramicin sodium dose, particularly in starter feeds where metabolic capacity is narrow. A validated changeover procedure therefore requires a flush batch of 200–500 kg ground maize or another non-medicated carrier per mixer cycle, followed by clean-out of elevator boots, drag conveyors, screw feeders, and pellet mill conditioner vent lines before the first semduramicin sodium batch is weighed. The first semduramicin sodium batch is not released until a monensin-specific ELISA or HPLC screen reads below the mill’s carryover threshold, commonly set at 1–2% of the previous drug’s authorised dose. Production records must document the flush sequence, equipment clean-out time, and the analytical result, because inspectors under 21 CFR Part 225/226 and auditors under GMP+ BA2 will review changeover records during inspections.

The addition ratio for semduramicin sodium after the flush remains 25 ppm in complete feed, supplied through a 5% premix at 0.5 kg per metric ton. If the mill uses a 0.5% intermediate pre-blend, the inclusion rate is correspondingly 5 kg per metric ton. Because semduramicin sodium is an ionophore, simultaneous use with tiamulin or other ionophore coccidiostats should be verified against the current label and national registration; published interaction data for semduramicin sodium are less extensive than for monensin, and the absence of a label combination does not imply compatibility. Terminal finished product types in this scenario are semduramicin sodium medicated broiler starter, grower, and finisher feeds produced only after the flush verification is signed off by the responsible quality unit.

Export-oriented premix plants generally convert semduramicin sodium API into free-flowing 5% granular premixes by sequential dry blending with calcium carbonate, ground corn cob, and 0.3–0.8% food-grade mineral oil. This converts a low-density, electrostatically active API powder into a granulated intermediate that can be metered through micro-dosing screws with acceptable recovery and reduced segregation during transit. The formulation addition ratio is 50 g semduramicin sodium per kg of premix; downstream feed mills apply 0.5 kg of this premix per metric ton of complete feed to achieve 25 ppm. Compliance rests on FAMI-QS, GMP+ BA2, ISO 22000, and, where export documents require, Regulation (EC) No 1831/2003 as the authorisation basis for the coccidiostat. Production equipment includes double-ribbon blenders or ploughshare mixers with batch cycle times of 15–20 min; post-mixing sieving at 1.0–2.0 mm removes agglomerates before bagging into 25 kg multi-wall paper sacks with an inner polyethylene liner. Finished product types include the 5% Type A medicated article, a 0.5% intermediate pre-blend for mills using high-inclusion micro-batching, and, where customer quality agreements require, a resale granulated premix with a mill certificate for homogeneity. Storage conditions are set at ambient temperature with humidity below 60% RH to prevent caking and carrier absorption shifts; warehouses should avoid direct sunlight and stacked-pallet moisture ingress.

The premix manufacturing route is not interchangeable with tablet, capsule, injection, or drinking-water formulation. The registered semduramicin sodium sources in major broiler-producing markets are feed-use coccidiostats; no injectable or oral solution premix is authorised as a veterinary medicinal product, and physical chemistry constraints reinforce that limitation. A 5% granular premix remains the commercially relevant downstream intermediate for semduramicin sodium API.

What Limits the Use of Semduramicin Sodium in Drinking Water or Injectable Routes?

The sodium salt form of semduramicin exhibits very low water solubility, and the registered use is as a feed additive rather than as a water-soluble veterinary medicinal product. From a formulation perspective, a drinking-water solution would require non-aqueous cosolvents, surfactants, or pH modifiers that are not part of the authorised feed additive dossier in major poultry markets and would introduce precipitation risk in hard water lines, biofilm-influenced drinker systems, and low-temperature medicated water tanks. Injectable administration would face a narrow therapeutic index, local tissue reaction potential, and the absence of pharmacokinetic residue data required by regulators for parenteral products. Published data for semduramicin sodium tablet, capsule, and injection formulations are limited, and no commercial tablet or capsule product based on semduramicin sodium is recognised as a standard veterinary dose form under 21 CFR 558.555 or Regulation (EC) No 1831/2003. The only validated addition ratio remains 25 ppm in dry complete feed; no parenteral or drinking-water addition rate has been established for broiler production.

Experimental capsules or tablets, if used in non-commercial pharmacokinetic or efficacy studies, would require a separate investigational veterinary product authorisation and would not fall within feed mill GMP. Downstream production for such forms would involve direct filling or granulation in a pharmaceutical facility with containment appropriate for an ionophore API, not a feed additive line. Terminal finished product types for commercial use therefore remain the 5% premix, the 0.5% intermediate pre-blend, and the final medicated broiler feed. This constraint is a regulatory and physicochemical boundary, not a formulation preference.

Finished feed testing for semduramicin sodium is performed by HPLC or LC-MS/MS in laboratories operating under ISO/IEC 17025, with methods validated for recovery, repeatability, and intermediate precision before release testing begins. Method validation spike levels are commonly prepared at 0.5×, 1×, and 2× the authorised 25 ppm dose, using blank feed matrix from the same mill and the same carrier system that will be used in production. Sampling procedures follow a defined protocol of 10–20 increment cores collected across the batch, riffling to obtain a representative laboratory sample, grinding below 1.0 mm, and extraction with a polar organic solvent system before reversed-phase HPLC separation and post-column derivatisation or tandem mass spectrometric detection. Matrix-matched calibration is necessary because mineral sources, fat coatings, and coccidiostat combination programmes can shift retention times and ion suppression in LC-MS/MS workflows. Release criteria for premix and finished feed include assay between 90% and 110% of label, confirmed identity against a certified reference standard, and homogeneity data expressed as a coefficient of variation below 5% across 9–10 sampling points for medicated feed. Terminal output from this scenario is a certificate of analysis for semduramicin sodium premix, intermediate pre-blend, and complete feed, with the analytical report traceable to the originating batch number and retained according to mill recordkeeping requirements under 21 CFR Part 225/226 or Regulation (EU) No 183/2005.

In routine QC experience, the main causes of batch failure in semduramicin sodium feed are sampling error from unmixed fines at the mixer discharge and sub-optimal extraction when over-dried feed contains heat-modified carrier starches. These failure modes are controlled by validating the sampling device, reducing dead zones in the mixer, and recording moisture content at the time of sampling. No inference about API potency should be made from a single low assay result without re-homogenising the retained sample and re-running the extraction under the same validated conditions.

Worker exposure to ionophore API is controlled by weigh-booth containment and closed transfer

Because semduramicin sodium API is handled as a low-density powder with pharmacological activity at milligram-level doses, worker exposure is controlled by negative-pressure weigh booths, HEPA-filtered local exhaust ventilation, and closed transfer systems. The weigh booth is operated with an average face velocity of 0.4–0.6 m/s, and all manual weigh-outs of neat API for experimental preblends or small premix batches are kept below 5 kg per weigh-out to limit the duration and quantity of open handling. Downstream production uses split butterfly valve charging, double-bag waste containment, and vacuum transfer into the blender. Compliance references include REACH Regulation (EC) No 1907/2006 for substance registration and safety data sheet duties, OSHA 29 CFR 1910.1200 for hazard communication in United States facilities, and local occupational exposure limits for ionophore-containing dusts. The end product of this containment sequence is a controlled semduramicin sodium pre-blend or 5% premix with substantially reduced dust potential compared with neat API; this pre-blend is then transferred to the feed mill in sealed, labelled bags under a chain-of-custody document. Any spillage of neat API is vacuumed with a HEPA-filtered unit and disposed of as chemical waste, not returned to the product stream.